Black Diamond Therapeutics to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Black Diamond Therapeutics (NASDAQ: BDTX) announced participation in four investor conferences in November–December 2025 with presentations by President and CEO Mark Velleca, M.D., Ph.D.

Scheduled events: Stifel Healthcare Conference fireside chat on Nov 11, 2025 at 9:20 AM ET; Guggenheim Healthcare Innovation fireside chat on Nov 12, 2025 at 9:00 AM ET; Piper Sandler Healthcare Conference fireside chat on Dec 4, 2025 at 1:00 PM ET; and Raymond James CEO Strategy Series on Dec 5, 2025 at 10:00 AM ET. Investors should contact their Raymond James representative to attend.

Webcasts will begin at each presentation start time and will be available on the investor relations section of the company website, with replays archived for 90 days.

CAMBRIDGE, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today announced its participation in upcoming investor conferences. Presentation details with President and Chief Executive Officer, Mark Velleca, M.D., Ph.D., are as follows:

• Stifel Healthcare Conference fireside chat at 9:20am ET on Tuesday, November 11, 2025
• Guggenheim 2nd Annual Healthcare Innovation Conference fireside chat at 9:00am ET on Wednesday, November 12, 2025
• Piper Sandler 37th Annual Healthcare Conference fireside chat at 1:00pm ET on Thursday, December 4, 2025
• Raymond James CEO Strategy Series at 10:00am ET on Friday, December 5, 2025. Investors who are interested in attending should reach out to their Raymond James representative

Webcasts will be available at the start of the presentations on the investor relations section of the Company’s website, www.blackdiamondtherapeutics.com. Replays of the presentations will also be available and archived on the site for 90 days.

About Black Diamond Therapeutics

Black Diamond Therapeutics is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The Company’s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system disease. The Company is advancing a Phase 2 non-small cell lung cancer (NSCLC) trial of silevertinib, a brain-penetrant fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR-mutant NSCLC and glioblastoma. For more information, please visit www.blackdiamondtherapeutics.com.

Contacts

For Investors:
investors@bdtx.com

For Media:
media@bdtx.com 

FAQ

When will Black Diamond Therapeutics (BDTX) present at the Stifel Healthcare Conference?

BDTX will present a fireside chat on Nov 11, 2025 at 9:20 AM ET.

How can investors watch Black Diamond Therapeutics (BDTX) presentations online?

Webcasts will be available at the start of each presentation on the company’s investor relations website and replays archived for 90 days.

What are the dates and times for BDTX presentations at Guggenheim and Piper Sandler conferences?

Guggenheim: Nov 12, 2025 at 9:00 AM ET; Piper Sandler: Dec 4, 2025 at 1:00 PM ET.

Who will represent Black Diamond Therapeutics (BDTX) at the investor conferences?

President and CEO Mark Velleca, M.D., Ph.D. will present at the listed events.

How can investors attend the Raymond James CEO Strategy Series presentation by BDTX?

Investors interested in attending should reach out to their Raymond James representative for access details.

How long will replay recordings of Black Diamond Therapeutics (BDTX) presentations remain available?

Replays will be archived on the investor relations website for 90 days after each presentation.